Processa Pharmaceuticals Inc (PCSA) FinancialsPCSAProcessa Pharmaceuticals Inc

Evaluating the bottom line, Processa Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -464.20%, provide a clear picture of how effectively PCSA converts its operational activities into shareholder value.

In the context of the broader market, PCSA competes directly with industry leaders such as SNOA and BGMS. With a market capitalization of $5.26M, it holds a significant position in the sector. When comparing efficiency, PCSA's gross margin of N/A stands against SNOA's 40.23% and BGMS's 23.51%. Such benchmarking helps identify whether Processa Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

PCSA has consistently reported negative net income, with the latest quarterly net income at -3,377,179 USD. The current ratio has dropped to 0.87, indicating potential liquidity issues. The company has a forward P/E ratio of 0, reflecting uncertainty in future earnings.